GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
MarketBeat on MSN11h
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Zacks Investment Research on MSN12h
LLY Rises More Than 4% in a Week: How to Play the Stock
Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just<a class="excerpt-read-more" href=" More ...
pharmaphorum3d
Lilly gets second approval, in Japan, for Alzheimer's drug
Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...